What’s Next for Neovascular Retinal Diseases? Preparing Patients for Impending Treatment Advances

1.25 CME
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

What’s Next for Neovascular Retinal Diseases? Preparing Patients for Impending Treatment Advances

Overview

Release Date: Monday, December 22, 2021
Expiration Date: Monday, December 22, 2022
Time to Complete Activity: 1.25 hours


Faculty

Carl D. Regillo, MD
Director, The Retina Service of Wills Eye Hospital
Partner, Mid Atlantic Retina
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA

Rishi P. Singh, MD
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Cleveland, OH


Provider Statement

This activity is provided by Paradigm Medical Communications, LLC.  Paradigm Medical Communications 


Disclosure of Financial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.


Target Audience

This activity is designed to meet the educational needs of comprehensive ophthalmologists. It may also benefit retina specialists and other clinicians involved in the care of patients with neovascular retinal diseases.


Program Description

Treatment of neovascular retinal diseases with intravitreal anti-vascular endothelial growth factor (VEGF), the long-running standard of care, is limited by a need for frequent repeat injections to derive optimal visual outcomes. The high treatment burden is associated with undertreatment (and, consequently, suboptimal visual outcomes) in the real world versus clinical trials. Innovative agents and delivery devices have the potential to upend onerous treatment paradigms while maintaining (and possibly even enhancing) efficacy. This educational initiative will outline the science behind novel agents and delivery modes that are poised to revolutionize the management of a variety of neovascular retinal diseases, so comprehensive ophthalmologists are better prepared to counsel patients about (and direct them toward) these groundbreaking treatment options.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify components of the angiopoietin (Ang)/Tie2 pathway that affect vascular stability, contributing to the pathophysiology of neovascular retinal diseases
  • Assess the safety and efficacy of novel neovascular retinal disease treatments and modes of delivery
  • Recognize key points for patient education regarding characteristics of new and emerging options for the treatment of neovascular retinal diseases, such as procedures, benefits, and risks

Accreditation

Physician Accreditation Statement
ACCME logoParadigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Instructions for Participation

To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.


Hardware/Software Requirements

This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.


Disclosures

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any financial relationship(s) occurring over the past 24 months with ineligible companies whose products or services are associated with the area of medicine featured in the activity. These relationship(s) are described below. Any potential conflicts of interest have been mitigated.

Faculty

Carl D. Regillo, MD
Consultant: Adverum Biotechnologies, Inc; Alderya Therapeutics, Inc.; Allergan, Inc.; Annexon Inc; Aviceda Therapeutics; Chengdu Kanghong Pharmaceutical Group Co., LTD; Eyepoint Pharmaceuticals, Inc; Genentech, Inc.; Graybug Vision, Inc.; IVERIC bio, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Inc; Merck & Co, Inc; NGM Biopharmaceuticals; Notal Vision, Inc.; Novartis; Ocugen, Inc; Opthea; Stealth BioTherapeutics Inc.; Takeda Pharmaceutical Company Ltd; Thea Pharma Inc; ZEISS International
Research Funding: Adverum Biotechnologies, Inc; Allergan, Inc.; Annexon Inc; Astellis Pharma US, Inc; Chengdu Kanghong Pharmaceutical Group Co., LTD; Eyepoint Pharmaceuticals, Inc; Genentech, Inc.; Graybug Vision, Inc.; IVERIC bio, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Inc; NGM Biopharmaceuticals; Notal Vision, Inc..; Novartis; Opthea; Regeneron Pharmaceuticals, Inc; REGENXBIO Inc
Stocks: IVERIC bio, Inc

Rishi P. Singh, MD
Consultant: Alcon; AsclepiX Therapeutics; Bausch and Lomb Incorporated; Genentech, Inc.; Gyroscope Therapeutics Limited; Novartis; Regeneron Pharmaceuticals, Inc
Research Funding: Apellis Pharmaceuticals, Inc; NGM Biopharmaceuticals

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are mitigated through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.


Copyright Statement

© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.


CME Questions?

If you have any questions or comments, please email us at contactus@paradigmmc.com